Stopped After enrolling 25 patients an interim analysis was done.The study was discontinued in the absence of the minimum number of 6 patients free of events
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG: 90Y-Ibritumomab Tiuxetan
Sponsor
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie